Ann: DEP irinotecan clinical data presented at AACR meeting, page-18

This my opinion only....

I think that the results we are expecting to be read out for the Ph2 Monotherapy arms of the DEP Dox/Cab trials are NOT going to be sufficient as a proof of concept. Hence why they are flogging out the prelim results for the DEP Iri combo arms, in the hope they will prop up the SP to prepare for the inevitable hit it is going to take when these impending Ph2 Mono arm results are read out.

I think we are in for some VERY challenging times ahead. Remember though the SP Floor will be $0.085 based off cash in bank.